Since many here thought that [Viekira] would have a 10-30% [market share], I would say that it not only the professional analysts that have a cloudy crystal ball, but all projections have to be suspect…
Agreed. Anyone can make a bad projection; my mockery of the Jefferies analyst is because: i) we haven’t yet seen all of ABBV/ENTA’s second-gen data to be reported this weekend; and ii) the analyst used the intentionally vague construct, “out years” (which could signify almost anything beyond 2017).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”